AnaptysBio plans to release further data on rosnilimab and other pipeline assets in 2025, including studies for ulcerative colitis. These developments highlight AnaptysBio's ongoing efforts in ...

The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with ... no longer appears in its pipeline listing.

Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the ...

Anaptys has cash, cash equivalents and investments greater than $420M as of December 31, 2024, and anticipates receipt of a $75M commercial ...

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.01, suggesting that its stock price is 99% less ...

(RTTNews) - AnaptysBio, Inc. (ANAB) on Monday announced that its Board of Directors has authorized a stock repurchase plan under which the company may repurchase up to $75 million of its ...

Investing.com -- Shares of AnaptysBio (NASDAQ:ANAB) climbed 12% today as the company announced a significant stock repurchase plan, signaling confidence in its financial position and future prospects.

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...